secwatch.observer — SEC 8-K summary
======================================

Issuer:     PALVELLA THERAPEUTICS, INC. (PVLA)
CIK:        0001583648
Form:       8-K
Filed at:   2026-02-24T23:59:59+00:00
Accession:  0001193125-26-065159
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Palvella Phase 3 SELVA study of QTORIN rapamycin meets primary endpoint with p<0.001; NDA planned H2 2026
--------------------------------------------------------------------------------

- Primary endpoint achieved: mean +2.13 improvement on mLM-IGA (p<0.001); all secondary endpoints met (p<0.001).
- 86% of completers rated 'Much Improved' or better; 95% improved at least 1 point.
- Well-tolerated: no drug-related SAEs; systemic rapamycin levels <2 ng/mL at all timepoints.
- NDA submission to FDA planned H2 2026; potential approval H1 2027 for first approved therapy for microcystic LMs.
- 98% of eligible participants chose to continue in extension period.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583648/000119312526065159/0001193125-26-065159-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583648/000119312526065159/pvla-20260224.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-065159

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer